ArticleApplied biochemistry and biotechnology2026
Phytochemical and Molecular Insights Into the Anti-PCOS Potential of Anchusa Strigosa: Targeting Hormones, Biochemical Markers, and WNT Genes.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder characterized by reproductive dysfunction, oxidative stress, and metabolic abnormalities. The present study investigated the therapeutic efficacy of a hydroalcoholic extract of Anchusa strigosa in a letrozole-induced PCOS rat model and explored its effects on ovarian Wnt signaling. Female Wistar rats (n = 36) were divided into normal control, PCOS control, A. strigosa low-dose (100 mg/kg), A. strigosa high-dose (250 mg/kg), and metformin (50 mg/kg) groups. Phytochemical profiling by FTIR and GC-MS identified 114 bioactive compounds enriched with phenolic, thiol, and isothiocyanate functional groups. Letrozole administration significantly increased body weight from 174.33 ± 1.80 g to 249.66 ± 1.66 g and elevated malondialdehyde levels from 45.42 ± 1.92 to 70.20 ± 1.51 while reducing superoxide dismutase from 28.97 ± 0.55 to 16.82 ± 0.59 and glutathione from 4.09 ± 0.07 to 1.83 ± 0.10 compared with normal controls. Treatment with A. strigosa, particularly at 250 mg/kg, markedly restored estrous cyclicity, reduced final body weight to 225.27 ± 0.57 g, decreased malondialdehyde to 60.90 ± 0.48, improved superoxide dismutase to 22.57 ± 0.27 and glutathione to 3.22 ± 0.09, normalized reproductive hormones and lipid profiles, restored ovarian morphology, and significantly upregulated ovarian Wnt7a and Wnt8b gene and protein expression. Although metformin produced slightly superior therapeutic effects, A. strigosa demonstrated comparable efficacy across most reproductive and metabolic parameters, highlighting its multi-target pharmacological potential. These findings suggest that A. strigosa represents a promising phytotherapeutic candidate for PCOS management. Future studies should focus on isolation of its active constituents, elucidation of the molecular mechanisms underlying Wnt pathway modulation, long-term safety evaluation, and well-designed clinical trials to establish its translational applicability in human PCOS.
Indexed as
Identifiers
42635896What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.